1. Which of the following botulinum toxin agents comes in a ready-to-use solution that does not require reconstitution?

2. Which of the following is NOT a United States Food and Drug Administration (FDA)-approved medical use of onabotulinumtoxinA (Botox®)?

3. Which of the following is a component of an effective prior authorization practice by managed care organizations according to the Academy of Managed Care Pharmacy (AMCP) Professional Practice Committee?

4. FB is a 54-year-old woman with chronic, severe migraines. She has received numerous medications to prevent her migraines with limited to no success. Her clinician wants to initiate therapy with onabotulinumtoxinA (Botox®). Which of the following counseling points is NOT correct?

5. Which of the following is NOT important for the appropriate use of botulinum toxin?

Evaluation Questions

6. How confident are in your treatment choice for FB?

« Return to Activity